carnitine has been researched along with Aura in 89 studies
Excerpt | Relevance | Reference |
---|---|---|
"Epileptic children treated with VPA and free of neurological disabilities are at risk for hyperammonemia that may be associated with hypocarnitinemia." | 9.14 | The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status. ( Abdella, MM; Hamed, SA, 2009) |
"This study was performed to evaluate carnitine deficiency in a large series of epilepsy children and adolescents treated with old and new antiepileptic drugs with or without ketogenic diet." | 9.12 | Plasma free carnitine in epilepsy children, adolescents and young adults treated with old and new antiepileptic drugs with or without ketogenic diet. ( Auricchio, G; Coppola, G; Epifanio, G; Federico, RR; Pascotto, A; Resicato, G, 2006) |
"Valproic acid (VPA) as a widely used primary medication in the treatment of epilepsy is associated with reversible or irreversible hepatotoxicity." | 9.01 | Valproic Acid and the Liver Injury in Patients with Epilepsy: An Update. ( Chen, F; Guo, HL; Hu, YH; Jing, X; Lu, XP; Ni, MM; Qiu, JC; Sun, JY; Wang, T; Xu, ZJ, 2019) |
"We measured carnitine levels before and after pivalate-conjugated antibiotic (PCA) use in six patients with epilepsy who were prescribed valproate (VPA)." | 8.02 | Carnitine supplementation prevents carnitine deficiency caused by pivalate-conjugated antibiotics in patients with epilepsy prescribed valproate. ( Azuma, Y; Iwayama, H; Kurahashi, H; Numoto, S; Okumura, A, 2021) |
"Overall, serum free carnitine levels showed significant negative correlations with epilepsy duration, VPA treatment duration, daily VPA dose, and blood VPA concentration." | 8.02 | Factors associated with blood carnitine levels in adult epilepsy patients with chronic valproic acid therapy. ( Miyaoka, H; Saito, M; Takizawa, T, 2021) |
"We measured the serum-free carnitine (FC), VPA, aspartate aminotransferase, alanine aminotransferase, amylase, and ammonia levels, and the platelet count, in 69 patients with childhood-onset epilepsy treated with VPA." | 8.02 | Effects of l-carnitine supplementation in patients with childhood-onset epilepsy prescribed valproate. ( Azuma, Y; Iwayama, H; Kurahashi, H; Numoto, S; Okumura, A; Takagi, M, 2021) |
"These findings suggest that carnitine deficiency is associated with the VPA dose and the serum VPA level in patients with bipolar disorder." | 7.96 | Association Between the Serum Carnitine Level and Ammonia and Valproic Acid Levels in Patients with Bipolar Disorder. ( Ishioka, M; Kubo, K; Miyazaki, K; Nakagami, T; Shimoda, K; Sugawara, N; Tarakita, N; Yasui-Furukori, N; Yokoyama, S, 2020) |
"We measured the serum carnitine levels in 94 consecutive patients with epilepsy, including the free carnitine (FC) and acylcarnitine fractions, using an enzyme cycling method." | 7.91 | Serum carnitine levels of children with epilepsy: Related factors including valproate. ( Iwayama, H; Kurahashi, H; Numoto, S; Okumura, A, 2019) |
"5%), with the diagnosis of idiopathic epilepsy and receiving valproic acid monotherapy were studied." | 7.88 | Evaluation ofserum free carnitine/acylcarnitine levels and left ventricular systolic functions in children with idiopathic epilepsy receiving valproic acid. ( Celik, H; Ince, H; Kulhas Celik, I; Sungur, M; Tasdemir, HA, 2018) |
"The free carnitine and acylcarnitines levels in 299 children with epilepsy on valproate monotherapy between June 2014 and September 2015 were compared with age- and sex-matched 299 healthy controls." | 7.88 | Carnitine Deficiency in Chinese Children with Epilepsy on Valproate Monotherapy. ( Hong, J; Qiliang, L; Wenqi, S, 2018) |
"Carnitine deficiency was found in approximately 17% of patients with epilepsy and was significantly associated with carnitine-free enteral formula only by tube feeding, number of AEDs taken (independent of VPA use), body weight (BW), body height and Gross Motor Function Classification System (GMFCS) score." | 7.81 | Carnitine deficiency: Risk factors and incidence in children with epilepsy. ( Fukuda, M; Ishii, E; Iwano, S; Kawabe, M; Kikuchi, C; Kuwabara, K; Morimoto, T; Suzuki, Y; Takehara, M; Wakamoto, H, 2015) |
"Valproic acid, a branched short-chain fatty acid, has numerous action mechanisms which turn it into a broad spectrum anticonvulsant drug and make its use possible in some other pathologies such as bipolar disorder." | 7.80 | Hyperammonemia associated with valproic acid concentrations. ( Alvariza, S; Fagiolino, P; Guevara, N; Ibarra, M; Magallanes, L; Maldonado, C; Olano, I; Olmos, I; Vázquez, M, 2014) |
"We could prove changes in acylcarnitine subspecies, which were associated with VPA treatment in children with epilepsy." | 7.74 | Effects of valproate on acylcarnitines in children with epilepsy using ESI-MS/MS. ( Gerstner, T; Koenig, SA; Kohlmueller, D; Longin, E; Mehlem, P; Schulze, A; Teich, M; Treiss, I; Werner, T, 2007) |
"Prolonged antiepilepsy drug treatment can result in secondary carnitine deficiency." | 7.72 | Serum carnitine levels during oxcarbazepine and carbamazepine monotherapies in children with epilepsy. ( Dirik, E; Iscan, A; Kurul, S, 2003) |
"In November 1996, a panel of pediatric neurologists met to update the consensus statement issued in 1989 by a panel of neurologists and metabolic experts on L-carnitine supplementation in childhood epilepsy." | 7.70 | L-carnitine supplementation in childhood epilepsy: current perspectives. ( Bohan, TP; Coulter, DL; De Vivo, DC; Dreifuss, FE; Greenwood, RS; Nordli, DR; Shields, WD; Stafstrom, CE; Tein, I, 1998) |
"Carnitine treatment does not always prevent the emergence of serious hepatotoxicity, but it does alleviate valproate-induced hyperammonemia." | 6.39 | Carnitine deficiency in epilepsy: Risk factors and treatment. ( Coulter, DL, 1995) |
"Epilepsy is one of the most common serious brain disorders, affecting about 1% of the population all over the world." | 5.72 | Anti-kindling effect of Ginkgo biloba leaf extract and L-carnitine in the pentylenetetrazol model of epilepsy. ( Abd El-Gawad, HS; Abd Elkader, HAE; Alhasani, RH; El-Sayed, SA; Essawy, AE; Tousson, E, 2022) |
"Acute encephalopathy with biphasic seizures and late reduced diffusion (AESD) is the most prevalent encephalopathy in Japanese children." | 5.51 | Early administration of vitamins B1 and B6 and l-carnitine prevents a second attack of acute encephalopathy with biphasic seizures and late reduced diffusion: A case control study. ( Fukui, KO; Ishiguro, A; Kashii, H; Kubota, M; Terashima, H, 2019) |
" Three groups of patients were studied: (A) epileptic under phenytoin monotherapy (n = 31); (B) with bipolar disorder under valproic acid treatment (n = 28); (C) elderly (n = 41)." | 5.22 | Carnitine and/or Acetylcarnitine Deficiency as a Cause of Higher Levels of Ammonia. ( Fagiolino, P; González, R; Guevara, N; Maldonado, C; Queijo, C; Vázquez, M, 2016) |
"The purpose of this study was to determine whether children with epilepsy undergoing valproate therapy and who are otherwise healthy have lower levels of serum and muscle carnitine." | 5.14 | Serum and muscle carnitine levels in epileptic children receiving sodium valproate. ( Anil, AB; Anil, M; Dilek, M; Helvaci, M; Kalenderer, O; Ozbal, E, 2009) |
"Epileptic children treated with VPA and free of neurological disabilities are at risk for hyperammonemia that may be associated with hypocarnitinemia." | 5.14 | The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status. ( Abdella, MM; Hamed, SA, 2009) |
"This study was performed to evaluate carnitine deficiency in a large series of epilepsy children and adolescents treated with old and new antiepileptic drugs with or without ketogenic diet." | 5.12 | Plasma free carnitine in epilepsy children, adolescents and young adults treated with old and new antiepileptic drugs with or without ketogenic diet. ( Auricchio, G; Coppola, G; Epifanio, G; Federico, RR; Pascotto, A; Resicato, G, 2006) |
" Antiquitin deficiency is the most common form of pyridoxine-dependent epilepsy." | 5.05 | Inherited Disorders of Lysine Metabolism: A Review. ( Bouchereau, J; Schiff, M, 2020) |
"Valproic acid (VPA) as a widely used primary medication in the treatment of epilepsy is associated with reversible or irreversible hepatotoxicity." | 5.01 | Valproic Acid and the Liver Injury in Patients with Epilepsy: An Update. ( Chen, F; Guo, HL; Hu, YH; Jing, X; Lu, XP; Ni, MM; Qiu, JC; Sun, JY; Wang, T; Xu, ZJ, 2019) |
"We measured the serum-free carnitine (FC), VPA, aspartate aminotransferase, alanine aminotransferase, amylase, and ammonia levels, and the platelet count, in 69 patients with childhood-onset epilepsy treated with VPA." | 4.02 | Effects of l-carnitine supplementation in patients with childhood-onset epilepsy prescribed valproate. ( Azuma, Y; Iwayama, H; Kurahashi, H; Numoto, S; Okumura, A; Takagi, M, 2021) |
"We measured carnitine levels before and after pivalate-conjugated antibiotic (PCA) use in six patients with epilepsy who were prescribed valproate (VPA)." | 4.02 | Carnitine supplementation prevents carnitine deficiency caused by pivalate-conjugated antibiotics in patients with epilepsy prescribed valproate. ( Azuma, Y; Iwayama, H; Kurahashi, H; Numoto, S; Okumura, A, 2021) |
" The aim of our study was to investigate the effects of valproic acid and carbamazepine monotherapy used in the treatment of epilepsy patients on serum adiponectin and carnitine levels." | 4.02 | The correlation between carbamazepine and valproic acid monotherapy with serum adiponectin and carnitine. ( Ceylan, M; İyigün, İ; Kızıltunç, A; Şimşek, F, 2021) |
"Overall, serum free carnitine levels showed significant negative correlations with epilepsy duration, VPA treatment duration, daily VPA dose, and blood VPA concentration." | 4.02 | Factors associated with blood carnitine levels in adult epilepsy patients with chronic valproic acid therapy. ( Miyaoka, H; Saito, M; Takizawa, T, 2021) |
"These findings suggest that carnitine deficiency is associated with the VPA dose and the serum VPA level in patients with bipolar disorder." | 3.96 | Association Between the Serum Carnitine Level and Ammonia and Valproic Acid Levels in Patients with Bipolar Disorder. ( Ishioka, M; Kubo, K; Miyazaki, K; Nakagami, T; Shimoda, K; Sugawara, N; Tarakita, N; Yasui-Furukori, N; Yokoyama, S, 2020) |
"To retrospectively assess the incidence of high beta hydroxybutyrate, low bicarbonate (BIC), high acyl carnitine, low selenium, low magnesium, low zinc, low phosphorus, in a cohort of supplemented patients treated with the ketogenic diet (KD) for medically intractable epilepsy." | 3.91 | Yield of laboratory testing in pediatric ketogenic diet patients: Critical assessment of abnormal results and impact on clinical care. ( Conley, A; Criteser, S; Joshi, C; Oliver, J; Sillau, S; Stillman, C; Zupec-Kania, B, 2019) |
"We measured the serum carnitine levels in 94 consecutive patients with epilepsy, including the free carnitine (FC) and acylcarnitine fractions, using an enzyme cycling method." | 3.91 | Serum carnitine levels of children with epilepsy: Related factors including valproate. ( Iwayama, H; Kurahashi, H; Numoto, S; Okumura, A, 2019) |
"5%), with the diagnosis of idiopathic epilepsy and receiving valproic acid monotherapy were studied." | 3.88 | Evaluation ofserum free carnitine/acylcarnitine levels and left ventricular systolic functions in children with idiopathic epilepsy receiving valproic acid. ( Celik, H; Ince, H; Kulhas Celik, I; Sungur, M; Tasdemir, HA, 2018) |
"The free carnitine and acylcarnitines levels in 299 children with epilepsy on valproate monotherapy between June 2014 and September 2015 were compared with age- and sex-matched 299 healthy controls." | 3.88 | Carnitine Deficiency in Chinese Children with Epilepsy on Valproate Monotherapy. ( Hong, J; Qiliang, L; Wenqi, S, 2018) |
"Carnitine deficiency was found in approximately 17% of patients with epilepsy and was significantly associated with carnitine-free enteral formula only by tube feeding, number of AEDs taken (independent of VPA use), body weight (BW), body height and Gross Motor Function Classification System (GMFCS) score." | 3.81 | Carnitine deficiency: Risk factors and incidence in children with epilepsy. ( Fukuda, M; Ishii, E; Iwano, S; Kawabe, M; Kikuchi, C; Kuwabara, K; Morimoto, T; Suzuki, Y; Takehara, M; Wakamoto, H, 2015) |
"Valproic acid, a branched short-chain fatty acid, has numerous action mechanisms which turn it into a broad spectrum anticonvulsant drug and make its use possible in some other pathologies such as bipolar disorder." | 3.80 | Hyperammonemia associated with valproic acid concentrations. ( Alvariza, S; Fagiolino, P; Guevara, N; Ibarra, M; Magallanes, L; Maldonado, C; Olano, I; Olmos, I; Vázquez, M, 2014) |
"Children with refractory epilepsy who suffered from severe liver function impairment during valproic acid (VPA) treatment at routine dosage were studied." | 3.78 | [Valproic acid-induced idiosyncratic liver injury in 4 cases]. ( Bao, XH; Jiang, YW; Liu, CT; Qin, J; Wu, XP; Xiong, H; Zhang, YH; Zhao, H, 2012) |
"This prospective study was designed to investigate whether or not monotherapy with sodium valproate (VPA) or oxcarbazepine (OXC) affects plasma levels of fatty acylcarnitine esters in children with epilepsy." | 3.77 | Analysis of acylcarnitine levels by tandem mass spectrometry in epileptic children receiving valproate and oxcarbazepine. ( Biberoglu, G; Cansu, A; Ezgu, FS; Hasanoglu, A; Hirfanoglu, TL; Serdaroglu, A; Tumer, L, 2011) |
"We could prove changes in acylcarnitine subspecies, which were associated with VPA treatment in children with epilepsy." | 3.74 | Effects of valproate on acylcarnitines in children with epilepsy using ESI-MS/MS. ( Gerstner, T; Koenig, SA; Kohlmueller, D; Longin, E; Mehlem, P; Schulze, A; Teich, M; Treiss, I; Werner, T, 2007) |
"Prolonged antiepilepsy drug treatment can result in secondary carnitine deficiency." | 3.72 | Serum carnitine levels during oxcarbazepine and carbamazepine monotherapies in children with epilepsy. ( Dirik, E; Iscan, A; Kurul, S, 2003) |
"To determine whether children with epilepsy undergoing valproate (VPA) antiepileptic therapy and who are otherwise healthy have a lower serum level of carnitine (CAR) and a higher plasma level of plasma ammonia than do normal children." | 3.70 | Valproate therapy does not deplete carnitine levels in otherwise healthy children. ( Hirose, S; Mitsudome, A; Muta, Y; Ogawa, A; Tomoda, Y; Yasumoto, S, 1998) |
"In November 1996, a panel of pediatric neurologists met to update the consensus statement issued in 1989 by a panel of neurologists and metabolic experts on L-carnitine supplementation in childhood epilepsy." | 3.70 | L-carnitine supplementation in childhood epilepsy: current perspectives. ( Bohan, TP; Coulter, DL; De Vivo, DC; Dreifuss, FE; Greenwood, RS; Nordli, DR; Shields, WD; Stafstrom, CE; Tein, I, 1998) |
"A 24-years-old woman with epilepsy treated with valproic acid developed disorientation, acalculia, perseveration, slow responsiveness and loss of memory." | 3.70 | [A case report of valproate encephalopathy]. ( Hirata, K; Katayama, S; Miyamoto, M; Miyamoto, T, 1999) |
"Carnitine metabolism was monitored in seven children started on a KD for pharmacoresistant epilepsy after a conventional initial fasting period." | 2.72 | Monitoring of ketogenic diet for carnitine metabolites by subcutaneous microdialysis. ( Baumeister, FA; Bieger, I; Busch, R; Busch, V; Gempel, K; Hack, A; Pascher, B, 2006) |
" However, in selected cases, depending on the effectiveness of the interventions, dosage reductions or discontinuation of medications may be possible." | 2.44 | Natural approaches to epilepsy. ( Gaby, AR, 2007) |
"Carnitine treatment does not always prevent the emergence of serious hepatotoxicity, but it does alleviate valproate-induced hyperammonemia." | 2.39 | Carnitine deficiency in epilepsy: Risk factors and treatment. ( Coulter, DL, 1995) |
"Carnitine is an important nutrient that is present in the diet (particularly in meat and dairy products) and is synthesized from dietary amino acids." | 2.38 | Carnitine, valproate, and toxicity. ( Coulter, DL, 1991) |
"Epilepsy is one of the most common serious brain disorders, affecting about 1% of the population all over the world." | 1.72 | Anti-kindling effect of Ginkgo biloba leaf extract and L-carnitine in the pentylenetetrazol model of epilepsy. ( Abd El-Gawad, HS; Abd Elkader, HAE; Alhasani, RH; El-Sayed, SA; Essawy, AE; Tousson, E, 2022) |
"Acute encephalopathy with biphasic seizures and late reduced diffusion (AESD) is the most prevalent encephalopathy in Japanese children." | 1.51 | Early administration of vitamins B1 and B6 and l-carnitine prevents a second attack of acute encephalopathy with biphasic seizures and late reduced diffusion: A case control study. ( Fukui, KO; Ishiguro, A; Kashii, H; Kubota, M; Terashima, H, 2019) |
"Carnitine levels were significantly low in patients under valproic acid therapy, however they were not found to be correlated with MDA, 8-OHdG or LFTs." | 1.51 | Effects of levetiracetam and valproic acid treatment on liver function tests, plasma free carnitine and lipid peroxidation in childhood epilepsies. ( Albayrak, P; Deda, G; Doğan, Ö; Eminoglu, FT; Haznedar, P; Öz Tunçer, G; Teber, S, 2019) |
" There is an ongoing debate whether this can be attributed to chronic use of antiepileptic drugs or to the epilepsy itself." | 1.33 | Antiepileptic drugs alter reproductive endocrine hormones in men with epilepsy. ( Bjørnenak, T; Gjerstad, L; Mørkrid, L; Mørland, T; Røste, LS; Saetre, ER; Taubøll, E, 2005) |
" We performed a cross-sectional surveillance study on pediatric patients taking valproate to evaluate the relationship between carnitine levels and demographic data including age, daily dosage of valproate, number of antiepileptic drugs, body mass index, and feeding problems." | 1.32 | Carnitine level in Chinese epileptic patients taking sodium valproate. ( Fok, TF; Fung, EL; Ho, CS; Lam, CW; Tang, NL, 2003) |
"Carnitine is an nonproteic nitrogenated compound acid present in all mammalian tissue and its principal activity is the long-chain fatty acid transport across the mitochondrial membrane for beta-oxidation." | 1.31 | [Antiepileptic drugs and carnitine]. ( Artuch, R; Campistol, J; Chávez, B; Vilaseca, MA, 2000) |
"Valproic acid (VPA) is an antiepileptic drug widely used in paediatrics." | 1.30 | [Evaluation of the effect of long term valproic acid treatment on plasma levels of carnitine, ammonia and amino acids related to the urea cycle in pediatric epileptic patients]. ( Jiménez, C; Lluch-Fernández, MD; Marchante-Serrano, C; Navarro-Quesada, FJ; Vaquero-Abellán, M, 1997) |
" In both group A and group B patients, plasma ammonia levels were correlated with the valproic acid dosage (r = 0." | 1.30 | Carnitine deficiency and hyperammonemia in children receiving valproic acid with and without other anticonvulsant drugs. ( Chiarelli, F; Greco, R; Morgese, G; Verrotti, A, 1999) |
"Free carnitine was low in tube-fed patients, as compared with that in oral-fed patients." | 1.28 | [The problems of valproate therapy in severely handicapped children--valproate induced hyperammonemia and hypocarnitinemia]. ( Iwamoto, H; Kobayashi, T; Matsui, K; Miyake, S; Ohtsuki, N; Yamada, M, 1991) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 5 (5.62) | 18.7374 |
1990's | 34 (38.20) | 18.2507 |
2000's | 19 (21.35) | 29.6817 |
2010's | 22 (24.72) | 24.3611 |
2020's | 9 (10.11) | 2.80 |
Authors | Studies |
---|---|
Essawy, AE | 1 |
El-Sayed, SA | 1 |
Tousson, E | 1 |
Abd El-Gawad, HS | 1 |
Alhasani, RH | 1 |
Abd Elkader, HAE | 1 |
McCarron, EP | 1 |
Khakwani, A | 1 |
Gannon, D | 1 |
Yokoyama, S | 2 |
Yasui-Furukori, N | 1 |
Nakagami, T | 1 |
Miyazaki, K | 1 |
Ishioka, M | 1 |
Tarakita, N | 1 |
Kubo, K | 1 |
Sugawara, N | 1 |
Shimoda, K | 1 |
Bouchereau, J | 1 |
Schiff, M | 1 |
Şimşek, F | 1 |
Ceylan, M | 1 |
Kızıltunç, A | 1 |
İyigün, İ | 1 |
Sanivarapu, R | 1 |
Sharma, R | 1 |
Akella, J | 1 |
Okumura, A | 3 |
Numoto, S | 3 |
Iwayama, H | 3 |
Azuma, Y | 2 |
Kurahashi, H | 3 |
Saito, M | 1 |
Takizawa, T | 1 |
Miyaoka, H | 1 |
Takagi, M | 1 |
Koga, S | 1 |
Kimata, T | 1 |
Yamanouchi, S | 1 |
Tsuji, S | 1 |
Yoshimura, K | 1 |
Araki, A | 1 |
Kaneko, K | 1 |
Qiliang, L | 1 |
Wenqi, S | 1 |
Hong, J | 1 |
Ono, H | 1 |
Kulhas Celik, I | 1 |
Tasdemir, HA | 1 |
Ince, H | 1 |
Celik, H | 1 |
Sungur, M | 1 |
Law, TH | 1 |
Volk, HA | 1 |
Pan, Y | 1 |
Zanghi, B | 1 |
Want, EJ | 1 |
Camilleri, L | 1 |
Joshi, C | 1 |
Stillman, C | 1 |
Criteser, S | 1 |
Oliver, J | 1 |
Conley, A | 1 |
Sillau, S | 1 |
Zupec-Kania, B | 2 |
Fukui, KO | 1 |
Kubota, M | 1 |
Terashima, H | 1 |
Ishiguro, A | 1 |
Kashii, H | 1 |
Haznedar, P | 1 |
Doğan, Ö | 1 |
Albayrak, P | 1 |
Öz Tunçer, G | 1 |
Teber, S | 1 |
Deda, G | 1 |
Eminoglu, FT | 2 |
Guo, HL | 1 |
Jing, X | 1 |
Sun, JY | 1 |
Hu, YH | 1 |
Xu, ZJ | 1 |
Ni, MM | 1 |
Chen, F | 1 |
Lu, XP | 1 |
Qiu, JC | 1 |
Wang, T | 1 |
Kato, A | 1 |
Vázquez, M | 2 |
Fagiolino, P | 2 |
Maldonado, C | 2 |
Olmos, I | 1 |
Ibarra, M | 1 |
Alvariza, S | 1 |
Guevara, N | 2 |
Magallanes, L | 1 |
Olano, I | 1 |
Fukuda, M | 1 |
Kawabe, M | 1 |
Takehara, M | 1 |
Iwano, S | 1 |
Kuwabara, K | 1 |
Kikuchi, C | 1 |
Wakamoto, H | 1 |
Morimoto, T | 1 |
Suzuki, Y | 1 |
Ishii, E | 1 |
Queijo, C | 1 |
González, R | 1 |
Anil, M | 1 |
Helvaci, M | 1 |
Ozbal, E | 1 |
Kalenderer, O | 1 |
Anil, AB | 1 |
Dilek, M | 1 |
Ozcelik, AA | 1 |
Okur, I | 1 |
Tumer, L | 2 |
Biberoglu, G | 2 |
Demir, E | 1 |
Hasanoglu, A | 2 |
Baumgartner, MR | 1 |
Hamed, SA | 1 |
Abdella, MM | 1 |
Bøhmer, T | 1 |
Bøen, A | 1 |
Høymork, SC | 1 |
Nakajima, Y | 1 |
Ito, T | 1 |
Maeda, Y | 1 |
Ichiki, S | 1 |
Kobayashi, S | 1 |
Ando, N | 1 |
Hussein, MH | 1 |
Kurono, Y | 1 |
Sugiyama, N | 2 |
Togari, H | 1 |
Davison, AS | 1 |
Milan, AM | 1 |
Roberts, NB | 1 |
Cansu, A | 1 |
Serdaroglu, A | 1 |
Hirfanoglu, TL | 1 |
Ezgu, FS | 1 |
Neal, EG | 1 |
Pfeifer, HH | 1 |
Xiong, H | 1 |
Liu, CT | 1 |
Zhang, YH | 1 |
Bao, XH | 1 |
Jiang, YW | 1 |
Zhao, H | 1 |
Wu, XP | 1 |
Qin, J | 1 |
Fung, EL | 1 |
Tang, NL | 1 |
Ho, CS | 1 |
Lam, CW | 1 |
Fok, TF | 1 |
Kurul, S | 1 |
Dirik, E | 1 |
Iscan, A | 1 |
Wu, SP | 1 |
Shyu, MK | 1 |
Liou, HH | 1 |
Gau, CS | 1 |
Lin, CJ | 1 |
Røste, LS | 1 |
Taubøll, E | 1 |
Mørkrid, L | 1 |
Bjørnenak, T | 1 |
Saetre, ER | 1 |
Mørland, T | 1 |
Gjerstad, L | 1 |
Kasturi, L | 1 |
Sawant, SP | 1 |
Coppola, G | 1 |
Epifanio, G | 1 |
Auricchio, G | 1 |
Federico, RR | 1 |
Resicato, G | 1 |
Pascotto, A | 1 |
Hack, A | 1 |
Busch, V | 1 |
Pascher, B | 1 |
Busch, R | 1 |
Bieger, I | 1 |
Gempel, K | 1 |
Baumeister, FA | 1 |
Werner, T | 1 |
Treiss, I | 1 |
Kohlmueller, D | 1 |
Mehlem, P | 1 |
Teich, M | 1 |
Longin, E | 1 |
Gerstner, T | 1 |
Koenig, SA | 1 |
Schulze, A | 1 |
Gaby, AR | 1 |
Vicente-Hernández, M | 1 |
Garcia-Garcia, P | 1 |
Gil-Nagel, A | 1 |
Lopez-Munoz, F | 1 |
Alamo, C | 1 |
Goto, S | 1 |
Seo, T | 1 |
Hagiwara, T | 1 |
Ueda, K | 1 |
Yamauchi, T | 1 |
Nagata, S | 1 |
Ando, Y | 1 |
Ishitsu, T | 1 |
Nakagawa, K | 1 |
Parikh, S | 1 |
Cohen, BH | 1 |
Gupta, A | 1 |
Lachhwani, DK | 1 |
Wyllie, E | 1 |
Kotagal, P | 1 |
Ohtani, Y | 2 |
Matsuda, I | 2 |
Christensen, E | 1 |
Brandt, NJ | 1 |
Schmalbruch, H | 1 |
Kamieniecka, Z | 1 |
Hertz, B | 1 |
Ruitenbeek, W | 1 |
Muro, H | 2 |
Tatsuhara, T | 1 |
Sugimoto, T | 3 |
Woo, M | 3 |
Nishida, N | 3 |
Murakami, K | 3 |
Yamaguchi, Y | 1 |
Zelnik, N | 1 |
Fridkis, I | 1 |
Gruener, N | 1 |
Freeman, JM | 1 |
Vining, EP | 1 |
Cost, S | 1 |
Singhi, P | 1 |
Kossak, BD | 1 |
Schmidt-Sommerfeld, E | 1 |
Schoeller, DA | 1 |
Rinaldo, P | 1 |
Penn, D | 1 |
Tonsgard, JH | 1 |
Melegh, B | 3 |
Pap, M | 1 |
Bock, I | 1 |
Rebouche, CJ | 1 |
Coulter, DL | 3 |
Beversdorf, D | 1 |
Allen, C | 1 |
Nordgren, R | 1 |
Böhles, H | 1 |
Sewell, AC | 1 |
Wenzel, D | 1 |
Hiraoka, A | 1 |
Arato, T | 1 |
Tominaga, I | 1 |
Keskin, S | 1 |
Seven, A | 1 |
Mert, M | 1 |
Akalp, F | 1 |
Yurdakul, F | 1 |
Candan, G | 1 |
Gidal, BE | 1 |
Inglese, CM | 1 |
Meyer, JF | 1 |
Pitterle, ME | 1 |
Antonopolous, J | 1 |
Rust, RS | 1 |
Navarro-Quesada, FJ | 1 |
Lluch-Fernández, MD | 1 |
Vaquero-Abellán, M | 1 |
Marchante-Serrano, C | 1 |
Jiménez, C | 1 |
Altunbaşak, S | 1 |
Baytok, V | 1 |
Tasouji, M | 1 |
Hergüner, O | 1 |
Burgut, R | 1 |
Kayrin, L | 1 |
Chung, S | 1 |
Choi, J | 1 |
Hyun, T | 1 |
Rha, Y | 1 |
Bae, C | 1 |
Hirose, S | 1 |
Mitsudome, A | 1 |
Yasumoto, S | 1 |
Ogawa, A | 1 |
Muta, Y | 1 |
Tomoda, Y | 1 |
Ballaban-Gil, K | 1 |
Callahan, C | 1 |
O'Dell, C | 1 |
Pappo, M | 1 |
Moshé, S | 1 |
Shinnar, S | 1 |
De Vivo, DC | 1 |
Bohan, TP | 1 |
Dreifuss, FE | 1 |
Greenwood, RS | 1 |
Nordli, DR | 1 |
Shields, WD | 1 |
Stafstrom, CE | 1 |
Tein, I | 1 |
Castro-Gago, M | 1 |
Eirís-Puñal, J | 1 |
Novo-Rodríguez, MI | 1 |
Couceiro, J | 1 |
Camiña, F | 1 |
Rodríguez-Segade, S | 1 |
Shuper, A | 1 |
Gutman, A | 2 |
Mimouni, M | 1 |
Verrotti, A | 1 |
Greco, R | 1 |
Morgese, G | 1 |
Chiarelli, F | 1 |
Sankar, R | 1 |
Sotero de Menezes, M | 1 |
Miyamoto, T | 1 |
Miyamoto, M | 1 |
Hirata, K | 1 |
Katayama, S | 1 |
Campistol, J | 1 |
Chávez, B | 1 |
Vilaseca, MA | 1 |
Artuch, R | 1 |
Maresová, D | 1 |
Rauchová, H | 1 |
Jandová, K | 1 |
Valkounová, I | 1 |
Koudelová, J | 1 |
Trojan, S | 1 |
DeVivo, DC | 1 |
Berry-Kravis, E | 1 |
Booth, G | 1 |
Sanchez, AC | 1 |
Woodbury-Kolb, J | 1 |
Sakemi, K | 1 |
Hayasaka, K | 1 |
Tahara, M | 1 |
Sanada, Y | 1 |
Takada, G | 1 |
Matsui, K | 1 |
Iwamoto, H | 1 |
Ohtsuki, N | 1 |
Kobayashi, T | 1 |
Miyake, S | 1 |
Yamada, M | 1 |
Opala, G | 1 |
Winter, S | 1 |
Vance, C | 1 |
Vance, H | 1 |
Hutchison, HT | 1 |
Linn, LS | 1 |
Thom, H | 1 |
Carter, PE | 1 |
Cole, GF | 1 |
Stevenson, KL | 1 |
Willmore, LJ | 1 |
Triggs, WJ | 1 |
Pellock, JM | 1 |
Shapira, Y | 1 |
Riva, R | 1 |
Zaccara, G | 1 |
Albani, F | 1 |
Galli, G | 1 |
Campostrini, R | 1 |
Paganini, M | 1 |
Baruzzi, A | 1 |
Kerner, J | 2 |
Acsádi, G | 2 |
Lakatos, J | 1 |
Sándor, A | 1 |
Sakane, Y | 1 |
Yasuhara, A | 1 |
Shuto, H | 1 |
Hatanaka, T | 1 |
Kobayashi, Y | 1 |
Komatsu, M | 1 |
Kodama, S | 1 |
Konishi, H | 1 |
Tanaka, K | 1 |
Momota, K | 1 |
Wada, H | 1 |
Matsuo, T | 1 |
Ninomiya, N | 1 |
Kispál, G | 1 |
Dani, M | 1 |
Kanayama, M | 1 |
Morishita, H | 1 |
Ishikawa, T | 1 |
Wada, Y | 1 |
Akiyama, T | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Efficacy, Tolerability and Adherence of the Modified Atkins Diet on Drug-resistant Epilepsy in Adults Patients[NCT03183076] | 14 participants (Actual) | Interventional | 2015-09-01 | Completed | |||
Effect of Adding Lamotrigine to Sodium Valproate in Childhood Epilepsy: Clinicolabratory Study[NCT05881928] | Phase 4 | 50 participants (Anticipated) | Interventional | 2023-07-25 | Not yet recruiting | ||
Estudio clínico Fase III Para Evaluar la Eficacia terapéutica en Pacientes Mexicanos Con Dislipidemia Mediante el Uso vía Oral de L-Carnitina + Atorvastatina Comparado Con Atorvastatina[NCT03696940] | Phase 3 | 120 participants (Actual) | Interventional | 2018-05-28 | Active, not recruiting | ||
In Vivo Study of Safety, Tolerability and Dosing Effect on SMN mRNA and Protein Levels of Valproic Acid in Patients With Spinal Muscular Atrophy[NCT00374075] | Phase 1 | 42 participants | Interventional | 2003-09-30 | Completed | ||
Phase I/II Trial of Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy Type I (CARNI-VAL Type I)[NCT00661453] | Phase 1/Phase 2 | 40 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
Multi-center Phase II Trial of Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy (SMA CARNI-VAL Trial)[NCT00227266] | Phase 2 | 94 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
(NCT00661453)
Timeframe: -2 weeks, time 0, 3 months, 6 months
Intervention | g (Mean) | |||||
---|---|---|---|---|---|---|
Lean Mass Baseline | Lean Mass 3 months | Lean Mass 6 months | Fat Mass Baseline | Fat Mass 3 months | Fat Mass 6 months | |
SMA Type 1 | 4317.15 | 4993.92 | 5133.83 | 3011.37 | 3618.25 | 4316.08 |
The maximum Compound Motor Action Potential (CMAP) is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This is done multiple times, the outcome used is the highest peak, or response observed. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
Intervention | mV (Mean) | |
---|---|---|
Baseline | 6 months | |
Cohort 1a Sitters Placebo Then Treatment | 2.28 | 2.32 |
Cohort 1b Sitters Treatment | 2.93 | 2.37 |
Cohort 2 Standers and Walkers - Treatment | 5.52 | 6.56 |
The maximum Compound Motor Action Potential (CMAP) is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This is done multiple times, the outcome used is the highest peak, or response observed. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
Intervention | mV (Median) | |
---|---|---|
Baseline | 6 months | |
Cohort 1a Sitters Placebo Then Treatment | 1.91 | 1.44 |
Cohort 1b Sitters Treatment | 2.2 | 1.8 |
Cohort 2 Standers and Walkers - Treatment | 5.3 | 5.85 |
The maximum Compound Motor Action Potential (CMAP) area is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This procedure is repeated multiple times. The maximum area is the response that results in the largest area under the response curve. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
Intervention | mVms (Mean) | |
---|---|---|
Baseline | 6 months | |
Cohort 1a Sitters Placebo Then Treatment | 5.46 | 5.28 |
Cohort 1b Sitters Treatment | 5.45 | 5.26 |
Cohort 2 Standers and Walkers - Treatment | 14.85 | 16.26 |
The maximum Compound Motor Action Potential (CMAP) area is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This procedure is repeated multiple times. The maximum area is the response that results in the largest area under the response curve. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
Intervention | mVms (Median) | |
---|---|---|
Baseline | 6 months | |
Cohort 1a Sitters Placebo Then Treatment | 3.6 | 3.74 |
Cohort 1b Sitters Treatment | 4.6 | 3.4 |
Cohort 2 Standers and Walkers - Treatment | 13.65 | 16.85 |
Comparison of Modified Hammersmith Change from baseline to 6 months. Scores range from 0 to 40. A higher score indicates a better outcome. This scale is used to assess gross motor abilities of non-ambulant children with SMA in multiple research trials as well as in clinical settings. (NCT00227266)
Timeframe: 0 months, 6 months
Intervention | Score (Mean) | ||
---|---|---|---|
Baseline visit (0 weeks) | 6 Month visit (V2) | Change from Baseline | |
Cohort 1a Sitters Placebo Then Treatment | 20.0 | 20.6 | 0.6 |
Cohort 1b Sitters Treatment | 16.6 | 16.8 | 0.2 |
"Baseline Modified Hammersmith Extend testing. The baseline test is the score they receive during their screening visits. This scale ranges from 0 to 56. A higher score indicates a better outcome.~This scale is used to assess gross motor abilities of children with SMA in multiple research trials as well as in clinical settings." (NCT00227266)
Timeframe: 1 month prior to enrollment, at enrollment (0 months)
Intervention | Score (Mean) | |
---|---|---|
Modified Hammersmith Extend at S1 (-4 weeks) | Modified Hammersmith Extend at S2 (0 weeks) | |
Cohort 2 Experimental | 47.0 | 48.3 |
11 reviews available for carnitine and Aura
Article | Year |
---|---|
L-carnitine supplementation as a potential therapy for suspected hyperammonaemic encephalopathy.
Topics: Adult; Anticonvulsants; Blood Chemical Analysis; Carnitine; Cerebral Palsy; Dietary Supplements; Epi | 2019 |
Inherited Disorders of Lysine Metabolism: A Review.
Topics: 2-Aminoadipic Acid; Aldehyde Dehydrogenase; Amino Acid Metabolism, Inborn Errors; Arginine; Brain; B | 2020 |
Lesson of the month 1: Sodium valproate-induced encephalopathy.
Topics: Aged; Ammonia; Anticonvulsants; Brain Diseases; Carnitine; Consciousness Disorders; Epilepsy; Humans | 2018 |
Valproic Acid and the Liver Injury in Patients with Epilepsy: An Update.
Topics: Anticonvulsants; Antioxidants; Carnitine; Chemical and Drug Induced Liver Injury; Epilepsy; Humans; | 2019 |
Carnitine, nutritional supplementation and discontinuation of ketogenic diet therapies.
Topics: Animals; Carnitine; Diet, Ketogenic; Dietary Supplements; Epilepsy; Evidence-Based Medicine; Humans; | 2012 |
Natural approaches to epilepsy.
Topics: Biotin; Carnitine; Diet; Dietary Supplements; Epilepsy; Fatty Acids, Essential; Folic Acid; Humans; | 2007 |
[Therapeutic approach to epilepsy from the nutritional view: current status of dietary treatment].
Topics: Anticonvulsants; Brain; Carnitine; Child; Clinical Trials as Topic; Diet, Carbohydrate-Restricted; D | 2007 |
Carnitine deficiency in epilepsy: Risk factors and treatment.
Topics: Carnitine; Epilepsy; Humans; Liver; Risk Factors; Valproic Acid; Vitamin B Deficiency | 1995 |
Metabolic and endocrine aspects of the ketogenic diet.
Topics: 3-Hydroxybutyric Acid; Anticonvulsants; Carnitine; Dietary Fats; Energy Metabolism; Epilepsy; Fatty | 1999 |
Valproate toxicity: risk-screening strategies.
Topics: Carnitine; Chemical and Drug Induced Liver Injury; Child; Enzymes; Epilepsy; Hepatic Encephalopathy; | 1991 |
Carnitine, valproate, and toxicity.
Topics: Carnitine; Chemical and Drug Induced Liver Injury; Child; Epilepsy; Hepatic Encephalopathy; Humans; | 1991 |
Carnitine, valproate, and toxicity.
Topics: Carnitine; Chemical and Drug Induced Liver Injury; Child; Epilepsy; Hepatic Encephalopathy; Humans; | 1991 |
Carnitine, valproate, and toxicity.
Topics: Carnitine; Chemical and Drug Induced Liver Injury; Child; Epilepsy; Hepatic Encephalopathy; Humans; | 1991 |
Carnitine, valproate, and toxicity.
Topics: Carnitine; Chemical and Drug Induced Liver Injury; Child; Epilepsy; Hepatic Encephalopathy; Humans; | 1991 |
Carnitine, valproate, and toxicity.
Topics: Carnitine; Chemical and Drug Induced Liver Injury; Child; Epilepsy; Hepatic Encephalopathy; Humans; | 1991 |
Carnitine, valproate, and toxicity.
Topics: Carnitine; Chemical and Drug Induced Liver Injury; Child; Epilepsy; Hepatic Encephalopathy; Humans; | 1991 |
Carnitine, valproate, and toxicity.
Topics: Carnitine; Chemical and Drug Induced Liver Injury; Child; Epilepsy; Hepatic Encephalopathy; Humans; | 1991 |
Carnitine, valproate, and toxicity.
Topics: Carnitine; Chemical and Drug Induced Liver Injury; Child; Epilepsy; Hepatic Encephalopathy; Humans; | 1991 |
Carnitine, valproate, and toxicity.
Topics: Carnitine; Chemical and Drug Induced Liver Injury; Child; Epilepsy; Hepatic Encephalopathy; Humans; | 1991 |
11 trials available for carnitine and Aura
Article | Year |
---|---|
Metabolic perturbations associated with the consumption of a ketogenic medium-chain TAG diet in dogs with idiopathic epilepsy.
Topics: Animals; Anticonvulsants; Carnitine; Chromatography, Liquid; Cross-Over Studies; Diet; Diet, Ketogen | 2018 |
Carnitine and/or Acetylcarnitine Deficiency as a Cause of Higher Levels of Ammonia.
Topics: Acetylcarnitine; Adolescent; Adult; Aged; Aged, 80 and over; Ammonia; Bipolar Disorder; Carnitine; E | 2016 |
Serum and muscle carnitine levels in epileptic children receiving sodium valproate.
Topics: Carnitine; Child; Child, Preschool; Enzyme Inhibitors; Epilepsy; Female; Humans; Male; Muscles; Seru | 2009 |
The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status.
Topics: Adolescent; Ammonia; Anticonvulsants; Carnitine; Child; Epilepsy; Female; Humans; Hyperammonemia; Ma | 2009 |
Plasma free carnitine in epilepsy children, adolescents and young adults treated with old and new antiepileptic drugs with or without ketogenic diet.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Carnitine; Child; Child, Preschool; Dietary Fats; | 2006 |
Monitoring of ketogenic diet for carnitine metabolites by subcutaneous microdialysis.
Topics: 3-Hydroxybutyric Acid; Acetylcarnitine; Biological Transport; Carnitine; Child; Child, Preschool; Di | 2006 |
Potential relationships between transaminase abnormality and valproic acid clearance or serum carnitine concentrations in Japanese epileptic patients.
Topics: Adolescent; Adult; Ammonia; Anticonvulsants; Body Weight; Carnitine; Chemical and Drug Induced Liver | 2008 |
Does carnitine administration improve the symptoms attributed to anticonvulsant medications?: a double-blinded, crossover study.
Topics: Carbamazepine; Carnitine; Child; Double-Blind Method; Epilepsy; Female; Health Status; Humans; Male; | 1994 |
The effect of carnitine supplementation in valproate-induced hyperammonaemia.
Topics: Adolescent; Adult; Ammonia; Anticonvulsants; Carnitine; Chemical and Drug Induced Liver Injury; Chil | 1996 |
Alterations in the carnitine metabolism in epileptic children treated with valproic acid.
Topics: Administration, Oral; Anticonvulsants; Carnitine; Child; Drug Therapy, Combination; Epilepsy; Female | 1997 |
Serum carnitine levels in epileptic children before and during treatment with valproic acid, carbamazepine, and phenobarbital.
Topics: Adolescent; Animals; Anticonvulsants; Carbamazepine; Carnitine; Child; Child, Preschool; Epilepsy; H | 1998 |
67 other studies available for carnitine and Aura
Article | Year |
---|---|
Anti-kindling effect of Ginkgo biloba leaf extract and L-carnitine in the pentylenetetrazol model of epilepsy.
Topics: Animals; Antioxidants; Carnitine; Epilepsy; Ginkgo biloba; Glutathione Peroxidase; Male; Oxidative S | 2022 |
Valproate induced carnitine deficiency and hyperammonaemia.
Topics: Amino Acid Metabolism, Inborn Errors; Anticonvulsants; Carnitine; Epilepsy; Humans; Hyperammonemia; | 2023 |
Association Between the Serum Carnitine Level and Ammonia and Valproic Acid Levels in Patients with Bipolar Disorder.
Topics: Ammonia; Anticonvulsants; Bipolar Disorder; Carnitine; Epilepsy; Female; Humans; Male; Middle Aged; | 2020 |
The correlation between carbamazepine and valproic acid monotherapy with serum adiponectin and carnitine.
Topics: Adiponectin; Adult; Anticonvulsants; Biomarkers; Carbamazepine; Carnitine; Dose-Response Relationshi | 2021 |
Thinking out of the box: management of valproic acid toxicity with carbapenems.
Topics: Adult; Anticonvulsants; Carbapenems; Carnitine; Epilepsy; Female; Humans; Meropenem; Valproic Acid | 2021 |
Carnitine supplementation prevents carnitine deficiency caused by pivalate-conjugated antibiotics in patients with epilepsy prescribed valproate.
Topics: Anti-Bacterial Agents; Carnitine; Dietary Supplements; Epilepsy; Humans; Valproic Acid | 2021 |
Factors associated with blood carnitine levels in adult epilepsy patients with chronic valproic acid therapy.
Topics: Adult; Amino Acids; Anticonvulsants; Carnitine; Epilepsy; Humans; Valproic Acid | 2021 |
Effects of l-carnitine supplementation in patients with childhood-onset epilepsy prescribed valproate.
Topics: Carnitine; Child; Dietary Supplements; Epilepsy; Humans; Retrospective Studies; Valproic Acid | 2021 |
Risk factors for sodium valproate-induced renal tubular dysfunction.
Topics: Adolescent; Adult; Anticonvulsants; beta 2-Microglobulin; Biomarkers; Carnitine; Chi-Square Distribu | 2018 |
Carnitine Deficiency in Chinese Children with Epilepsy on Valproate Monotherapy.
Topics: Anticonvulsants; Beijing; Carnitine; Case-Control Studies; Child, Preschool; Deficiency Diseases; Ep | 2018 |
Sodium valproate-induced Fanconi syndrome in two severely disabled patients receiving carnitine supplementation.
Topics: Adult; Anticonvulsants; Carnitine; Disabled Persons; Epilepsy; Fanconi Syndrome; Female; Humans; Int | 2019 |
Evaluation ofserum free carnitine/acylcarnitine levels and left ventricular systolic functions in children with idiopathic epilepsy receiving valproic acid.
Topics: Adolescent; Anticonvulsants; Biomarkers; Carnitine; Child; Child, Preschool; Electrocardiography; Ep | 2018 |
Yield of laboratory testing in pediatric ketogenic diet patients: Critical assessment of abnormal results and impact on clinical care.
Topics: Adolescent; Carnitine; Child; Child, Preschool; Clinical Laboratory Techniques; Cohort Studies; Crit | 2019 |
Serum carnitine levels of children with epilepsy: Related factors including valproate.
Topics: Adolescent; Body Mass Index; Carnitine; Child; Child, Preschool; Cognitive Dysfunction; Epilepsy; Fe | 2019 |
Early administration of vitamins B1 and B6 and l-carnitine prevents a second attack of acute encephalopathy with biphasic seizures and late reduced diffusion: A case control study.
Topics: Brain Diseases; Carnitine; Case-Control Studies; Child, Preschool; Diagnosis, Differential; Disease | 2019 |
Effects of levetiracetam and valproic acid treatment on liver function tests, plasma free carnitine and lipid peroxidation in childhood epilepsies.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Anticonvulsants; Carnitine; Child; Deoxyguanosine; Epilepsy; Female; Hu | 2019 |
[Carnitine deficiency with valproate sodium therapy--the difference by normal diet and enteral nutrition].
Topics: Adolescent; Adult; Carnitine; Child; Child, Preschool; Dietary Supplements; Enteral Nutrition; Epile | 2013 |
Hyperammonemia associated with valproic acid concentrations.
Topics: Adolescent; Adult; Ammonia; Bipolar Disorder; Carnitine; Child; Dietary Supplements; Dose-Response R | 2014 |
Carnitine deficiency: Risk factors and incidence in children with epilepsy.
Topics: Adolescent; Anticonvulsants; Cardiomyopathies; Carnitine; Case-Control Studies; Child; Child, Presch | 2015 |
3-Methylcrotonyl-CoA carboxylase deficiency: phenotypic variability in a family.
Topics: Adult; Brain; Carbon-Carbon Ligases; Carnitine; Cells, Cultured; Child, Preschool; DNA Mutational An | 2009 |
Valproate-induced hyperammonemic encephalopathy, rapidly improved by i.v. carnitine and glucose/thiamine.
Topics: Aged; Ammonia; Anticonvulsants; Brain Diseases, Metabolic; Carnitine; Dose-Response Relationship, Dr | 2010 |
Evaluation of valproate effects on acylcarnitine in epileptic children by LC-MS/MS.
Topics: Adolescent; Anticonvulsants; Carnitine; Child; Child, Preschool; Chromatography, Liquid; Epilepsy; F | 2011 |
The consequences of valproate overdose.
Topics: Acid-Base Equilibrium; Acidosis, Lactic; Adult; Anticonvulsants; Carnitine; Drug Overdose; Epilepsy; | 2011 |
Analysis of acylcarnitine levels by tandem mass spectrometry in epileptic children receiving valproate and oxcarbazepine.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Carnitine; Child; Child, Preschool; Chromatography, High | 2011 |
[Valproic acid-induced idiosyncratic liver injury in 4 cases].
Topics: Anticonvulsants; Biomarkers; Carnitine; Chemical and Drug Induced Liver Injury; Child; Child, Presch | 2012 |
Carnitine level in Chinese epileptic patients taking sodium valproate.
Topics: Adolescent; Anticonvulsants; Asian People; Carnitine; Child; Epilepsy; Female; Humans; Male; Metabol | 2003 |
Serum carnitine levels during oxcarbazepine and carbamazepine monotherapies in children with epilepsy.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Carnitine; Child; Epilepsy; Female; Humans; Male | 2003 |
Interaction between anticonvulsants and human placental carnitine transporter.
Topics: Acetates; Amines; Aminoisobutyric Acids; Anticonvulsants; Carnitine; Carrier Proteins; Culture Techn | 2004 |
Antiepileptic drugs alter reproductive endocrine hormones in men with epilepsy.
Topics: Adult; Age Factors; Androstenedione; Anticonvulsants; C-Peptide; Carbamazepine; Carnitine; Dihydrote | 2005 |
Sodium valproate -- induced skeletal myopathy.
Topics: Anticonvulsants; Carbamazepine; Carnitine; Child, Preschool; Epilepsy; Humans; Male; Muscular Diseas | 2005 |
Effects of valproate on acylcarnitines in children with epilepsy using ESI-MS/MS.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Carnitine; Chemical and Drug Induced Liver Injury; Child | 2007 |
Metabolic testing in the pediatric epilepsy unit.
Topics: Adolescent; Adult; Amino Acids; Ammonia; Carnitine; Child; Child, Preschool; Electroencephalography; | 2008 |
Valproate treatment and carnitine deficiency.
Topics: Animals; Carnitine; Epilepsy; Liver; Muridae; Valproic Acid | 1984 |
Muscle cytochrome c oxidase deficiency accompanied by a urinary organic acid pattern mimicking multiple acyl-CoA dehydrogenase deficiency.
Topics: Acids; Acyl-CoA Dehydrogenases; Carnitine; Cytochrome-c Oxidase Deficiency; Epilepsy; Humans; Infant | 1993 |
Determination of urinary valproylcarnitine by gas chromatography-mass spectrometry with selected-ion monitoring.
Topics: Calibration; Carbon Tetrachloride; Carnitine; Dimethylformamide; Drug Stability; Epilepsy; Gas Chrom | 1995 |
Reduced carnitine and antiepileptic drugs: cause relationship or co-existence?
Topics: Adolescent; Anticonvulsants; Carbamazepine; Carnitine; Child; Child, Preschool; Epilepsy; Female; Hu | 1995 |
Impaired fatty acid oxidation in children on valproic acid and the effect of L-carnitine.
Topics: Adolescent; Adult; Breath Tests; Carnitine; Child; Child, Preschool; Chromatography, High Pressure L | 1993 |
Relationship of carnitine and carnitine precursors lysine, epsilon-N-trimethyllysine, and gamma-butyrobetaine in drug-induced carnitine depletion.
Topics: Adolescent; Bacteriuria; Betaine; Carnitine; Child; Child, Preschool; Creatinine; Epilepsy; Female; | 1993 |
Effect of L-carnitine supplementation on acute valproate intoxication.
Topics: Ammonia; Carnitine; Coma; Drug Overdose; Epilepsy; Humans; Infant; Male; Oxidation-Reduction; Valpro | 1996 |
Valproate induced encephalopathy treated with carnitine in an adult.
Topics: Adult; Anticonvulsants; Carnitine; Epilepsy; Female; Hepatic Encephalopathy; Humans; Liver; Valproic | 1996 |
Reduction in blood free carnitine levels in association with changes in sodium valproate (VPA) disposition in epileptic patients treated with VPA and other anti-epileptic drugs.
Topics: Adult; Aged; Anticonvulsants; Carnitine; Epilepsy; Female; Humans; Male; Middle Aged; Valproic Acid | 1997 |
Could L-carnitine be an acute energy inducer in catabolic conditions?
Topics: Carnitine; Child; Child, Preschool; Energy Metabolism; Epilepsy; Female; Humans; Infant; Male; Shock | 1997 |
Diet- and valproate-induced transient hyperammonemia: effect of L-carnitine.
Topics: Administration, Oral; Adolescent; Ammonia; Anticonvulsants; Carnitine; Child; Diet; Epilepsy; Female | 1997 |
[Evaluation of the effect of long term valproic acid treatment on plasma levels of carnitine, ammonia and amino acids related to the urea cycle in pediatric epileptic patients].
Topics: Adolescent; Amino Acids; Ammonia; Anticonvulsants; Carnitine; Child; Child, Preschool; Epilepsy; Glu | 1997 |
Asymptomatic hyperammonemia in children treated with valproic acid.
Topics: Adolescent; Adult; Ammonia; Anticonvulsants; Carnitine; Child; Child, Preschool; Epilepsy; Female; H | 1997 |
Valproate therapy does not deplete carnitine levels in otherwise healthy children.
Topics: Adolescent; Adult; Ammonia; Carnitine; Case-Control Studies; Child; Epilepsy; Female; Humans; Male; | 1998 |
Complications of the ketogenic diet.
Topics: Adolescent; Carnitine; Child; Child, Preschool; Combined Modality Therapy; Epilepsy; Follow-Up Studi | 1998 |
L-carnitine supplementation in childhood epilepsy: current perspectives.
Topics: Age Factors; Ammonia; Anticonvulsants; Carnitine; Chemical and Drug Induced Liver Injury; Child; Chi | 1998 |
Intractable epilepsy.
Topics: Abdominal Pain; Anticonvulsants; Carnitine; Child, Preschool; Epilepsy; Humans; Male; Valproic Acid | 1999 |
Carnitine deficiency and hyperammonemia in children receiving valproic acid with and without other anticonvulsant drugs.
Topics: Adolescent; Adult; Ammonia; Anticonvulsants; Carnitine; Child; Child, Preschool; Epilepsy; Female; H | 1999 |
[A case report of valproate encephalopathy].
Topics: Adult; Ammonia; Anticonvulsants; Biomarkers; Brain; Brain Diseases; Carnitine; Epilepsy; Female; Hum | 1999 |
[Antiepileptic drugs and carnitine].
Topics: Adolescent; Anticonvulsants; Carnitine; Child; Child, Preschool; Epilepsy; Female; Humans; Infant; M | 2000 |
Carnitine pretreatment can partially change the excitability of the immature nervous tissue.
Topics: Animals; Atmosphere Exposure Chambers; Brain; Carnitine; Electric Stimulation; Electrodes, Implanted | 2001 |
Effect of L-carnitine treatment for valproate-induced hepatotoxicity.
Topics: Anticonvulsants; Carnitine; Chemical and Drug Induced Liver Injury; Epilepsy; Humans; Liver Diseases | 2002 |
Carnitine levels and the ketogenic diet.
Topics: Adolescent; Adult; Carnitine; Child; Child, Preschool; Dietary Carbohydrates; Dietary Fats; Epilepsy | 2001 |
The effect of carnitine on the metabolism of valproic acid in epileptic patients.
Topics: Adolescent; Adult; Carnitine; Child; Epilepsy; Female; Half-Life; Humans; Male; Valproic Acid | 1992 |
[The problems of valproate therapy in severely handicapped children--valproate induced hyperammonemia and hypocarnitinemia].
Topics: Adolescent; Adult; Ammonia; Carnitine; Child; Child, Preschool; Disabled Persons; Enteral Nutrition; | 1991 |
The effect of valproic acid on plasma carnitine levels.
Topics: Adolescent; Anticonvulsants; Carnitine; Child; Child, Preschool; Dose-Response Relationship, Drug; D | 1991 |
Ammonia and carnitine concentrations in children treated with sodium valproate compared with other anticonvulsant drugs.
Topics: Adolescent; Ammonia; Anticonvulsants; Carnitine; Child; Child, Preschool; Epilepsy; Erythrocytes; Fe | 1991 |
Muscle carnitine deficiency in patients using valproic acid.
Topics: Carnitine; Child, Preschool; Epilepsy; Humans; Infant; Muscles; Valproic Acid | 1991 |
Effects of acute valproic acid administration on carnitine plasma concentrations in epileptic patients.
Topics: Adult; Ammonia; Carnitine; Epilepsy; Humans; Phenobarbital; Phenytoin; Valproic Acid | 1991 |
L-carnitine replacement therapy in chronic valproate treatment.
Topics: Adolescent; Carnitine; Child; Chronic Disease; Epilepsy; Female; Humans; Ketone Bodies; Lipid Metabo | 1990 |
Valproate-induced hepatoxicity: protective effect of L-carnitine supplementation.
Topics: Anticonvulsants; Carnitine; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Dose-Re | 1990 |
Valproate-associated hyperammonemia and DL-carnitine supplement.
Topics: Adolescent; Adult; Ammonia; Carbamazepine; Carnitine; Child; Child, Preschool; Disabled Persons; Dru | 1987 |
Renal handling of carnitine in children with carnitine deficiency and hyperammonemia associated with valproate therapy.
Topics: Ammonia; Carnitine; Epilepsy; Humans; Infant; Intellectual Disability; Kidney; Metabolic Clearance R | 1986 |
Effect of chronic valproic acid treatment on plasma and urine carnitine levels in children: decreased urinary excretion.
Topics: Adolescent; Carnitine; Child; Epilepsy; Humans; Male; Valproic Acid | 1987 |
[Effects of valproate on mitochondrial function in epileptic patients].
Topics: Adolescent; Ammonia; Carnitine; Child; Child, Preschool; Epilepsy; Humans; Lactates; Lactic Acid; Mi | 1985 |